OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oncocyte continues global expansion of DetermaRx with its second international agreement this year Oncocyte continues global expansion of DetermaRx with its second international agreement this year

Oncocyte Announces Distribution Agreement with ProGenetics Ltd, Expanding Commercial Availability of DetermaRx™ to Israel

Testing volume for DetermaRx™ doubled from Q1 2020 to Q2 2020 despite challenging COVID-19 macroenvironment Testing volume for DetermaRx™ doubled from Q1 2020 to Q2 2020 despite challenging COVID-19 macroenvironment

Oncocyte Provides an Update on the Rapid Growth of DetermaRx™ Physician Adoption and Testing Volume

Oncocyte: Despite The Bad Result Of DetermaDX The Comany Still Has Bullish Potential

On June 29 OncoCyte reported the results of the clinical validation of the DetermaDx test with very bad news: The results obtained failed to reach the target set.

Oncocyte: Despite The Bad Result Of DetermaDX The Company Still Has Bullish Potential

 Prospective, blinded clinical validation study did not achieve pre-defined endpoint of improvement over routinely used clinical factors for managing patients with radiologically identified lung nodules

Oncocyte Announces Completion of DetermaDx™ Clinical Validation Study

Oncocyte has received its first diagnostic revenues from commercial payers

Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx™ Reimbursements

OncoCyte: Already A Commercial Stage Company With Enormous Revenue Potential

Oncocyte Corporation (OCX) CEO Ronald Andrews on Q1 2020 Results - Earnings Call Transcript

Announced Final Medicare LCD from Palmetto for DetermaRx™, Potentially Establishing Medicare Coverage for up to 70% of Eligible Early-Stage NSCLC Patients

Oncocyte Provides Corporate Update And Reports First Quarter 2020 Financial Results

Abstracts selected for oral presentation at the American Thoracic Society 2020 International Conference and published in American Journal of Respiratory and Clinical Care Medicine

Oncocyte Announces the Publication of New Long-Term Patient Follow Up Data for DetermaRx™ and Research Describing the IRENE Cohort Being Used in the Development of DetermaDx™

May lead to Medicare coverage for up to 70% of eligible early-stage lung cancer patients May lead to Medicare coverage for up to 70% of eligible early-stage lung cancer patients

Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx™

Further strengthens balance sheet to support ongoing commercial and development activities Further strengthens balance sheet to support ongoing commercial and development activities

Oncocyte Announces $10.7 Million Registered Offering

Co-Diagnostics

Establishment Labs Holdings Inc

Novocure

Medical Services Outlook Bright Amid Coronavirus Crisis

OncoCyte Corporation (OCX) CEO Ronald Andrews on Q4 2019 Results - Earnings Call Transcript

Company completes CLIA Validation of DetermaIO™, previously the Insight Genetics IM Score Test,  establishing the test as a reliable and robust assay for identifying patients likely to respond to checkpoint inhibitor therapy

Oncocyte Announces the Launch of CLIA-validated DetermaIO™, a Novel Gene Expression-Based Immune Therapy Response Predictor, for Research Use by Biopharmaceutical Companies and Researchers

Acquisition broadens suite of molecular diagnostic tests to include potentially transformative immunotherapy response prediction test demonstrated to outperform PD-L1 and TMB

Oncocyte Closes Merger Agreement to Acquire Insight Genetics

OncoCyte Enters Into The Cancer Immunotherapy Field With The Acquisition Of Insight Genetics

Leonard Cancer Institute at Mission Hospital, California and Florida Precision Oncology sign up as early access sites for the test    Canadian regulatory approval received allowing for path to reimbursement

Oncocyte Announces the Commercial Availability of DetermaRx™, the First Test for Chemotherapy Benefit Prediction in Patients with Early Stage Non-Small Cell Lung Cancer

OncoCyte Meets An Important Milestone With The Completion Of CLIA Validation Of DetermaDx

Company expects to complete clinical validation study of DetermaDx, previously DetermaVu™, in Q2 2020 Company expects to complete clinical validation study of DetermaDx, previously DetermaVu™, in Q2 2020

OncoCyte Announces Successful Completion of CLIA Validation Study of DetermaDx™

Proceeds strengthen balance sheet to support 2020 commercial launch and development activities Proceeds strengthen balance sheet to support 2020 commercial launch and development activities

OncoCyte Announces $7.6 Million Registered Offering

OncoCyte Accelerates The Transition To A Commercial Phase Company

OncoCyte Corporation (OCX) CEO Ronald Andrews on Q3 2019 Results - Earnings Call Transcript

The goals of the collaboration include several key initiatives, including partnerships with clinical trial networks and increasing access to molecular testing for the early diagnosis and management of lung cancer The goals of the collaboration include several key initiatives, including partnerships with clinical trial networks and increasing access to molecular testing for the early diagnosis and management of lung cancer

Oncocyte Announces Strategic Support of GO2 Foundation for Lung Cancer

ALAMEDA, Calif., Oct.  15, 2019  (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the number of unnecessary biopsies and associated complications, during the CHEST Annual Meeting 2019. This year’s CHEST meeting is being held October 19-23, 2019 at the Ernest N. Morial Convention Center in New Orleans, LA.

News for OncoCyte Stock (OCX)